Unit of Urology, University Vita-Salute, San Raffaele Scientific Institute, Milan, Italy; Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Edinburgh Urological Cancer Group, University of Edinburgh, Western General Hospital, Edinburgh, UK.
Eur Urol Focus. 2018 Dec;4(6):972-977. doi: 10.1016/j.euf.2017.02.020. Epub 2017 Mar 21.
A non-negligible proportion of individuals diagnosed with cT1 renal cell carcinoma (RCC) are upstaged to pT3a at final pathology. Few data on oncological outcomes for these patients are available to determine whether partial nephrectomy (PN) might jeopardise cancer control.
To assess, within an international multi-institutional collaboration, whether PN might undermine cancer control relative to radical nephrectomy (RN) in RCC patients with unexpected pT3a disease.
DESIGN, SETTING, AND PARTICIPANTS: International multi-institutional collaboration including patients with cT1abN0M0-pT3a RCC.
PN or RN.
We used Kaplan-Meier analyses, before and after propensity-score matching, to evaluate differences in metastatic progression (MP) and cancer-specific mortality (CSM) rates during follow-up. Univariable and multivariable Cox regression analyses were used to assess predictors of MP and CSM.
Overall, 309 patients with cT1abN0M0 RCC (cT1aN0M0, n=107, 34.6%; cT1bN0M0, n=202, 65.4%) had pT3a disease according to final pathology. Patients were treated with either PN (n=71, 23%) or RN (n=238, 77%). MP at 1, 2, and 5 yr was detected in 9.1%, 13.3%, and 24.1% of patients, respectively. CSM was 3.5%, 10.7%, and 18.4% at 1, 2, and 5 yr, respectively. After matching, no difference in terms of MP or CSM was observed between the PN and RN cohorts (both p>0.3). On multivariable analysis, type of surgery (PN vs RN) was not an independent predictor of either MP (p=0.3) or CSM (p=0.4). Limitations include the retrospective design.
In patients with unexpected pT3a RCC at final pathology, PN does not appear to jeopardise cancer control with regard to MP and CSM.
Cancer control is similar between patients treated with removal of the entire kidney and those with only partial removal, even if the final histology examination demonstrates a tumour that is unexpectedly not confined within the kidney.
相当一部分诊断为 cT1 肾细胞癌 (RCC) 的患者在最终病理检查时被升级为 pT3a。目前尚缺乏有关这些患者肿瘤学结局的数据,无法确定部分肾切除术 (PN) 是否会影响癌症控制。
在国际多机构合作中评估,对于最终病理检查发现意外 pT3a 疾病的 RCC 患者,PN 是否会相对于根治性肾切除术 (RN) 危及癌症控制。
设计、地点和参与者:包括 cT1abN0M0-pT3a RCC 患者的国际多机构合作。
PN 或 RN。
我们使用 Kaplan-Meier 分析,在进行倾向评分匹配之前和之后,评估随访期间转移进展 (MP) 和癌症特异性死亡率 (CSM) 率的差异。单变量和多变量 Cox 回归分析用于评估 MP 和 CSM 的预测因素。
总体而言,309 例 cT1abN0M0 RCC 患者 (cT1aN0M0,n=107,34.6%;cT1bN0M0,n=202,65.4%) 根据最终病理检查结果为 pT3a 疾病。患者接受 PN(n=71,23%) 或 RN(n=238,77%) 治疗。1、2 和 5 年时的 MP 分别为 9.1%、13.3%和 24.1%。1、2 和 5 年时的 CSM 分别为 3.5%、10.7%和 18.4%。在匹配后,PN 和 RN 队列之间在 MP 或 CSM 方面没有差异 (均 p>0.3)。多变量分析显示,手术类型 (PN 与 RN) 不是 MP(p=0.3) 或 CSM(p=0.4) 的独立预测因素。局限性包括回顾性设计。
在最终病理检查显示意外 pT3a RCC 的患者中,PN 似乎不会危及 MP 和 CSM 方面的癌症控制。
即使最终组织学检查显示肿瘤出乎意料地未局限于肾脏,接受整个肾脏切除的患者和仅接受部分肾脏切除的患者的癌症控制效果相似。